UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
German Inflation Accelerates to 2.9% in August 
South Korea GDP Surges on Chip and AI Boom 
China Boosts Gold Reserves by 650,000 Ounces as Prices Rally 
US Stock Futures Mixed as Fed Rate Hike Bets Rise 
Asian Stocks Fall as Oil Tops $100, Yields Rise 
Japan GDP Growth Beats Forecast, Boosting BOJ Rate Hike Bets 
Canada Retaliatory Tariffs on U.S. Goods Take Effect 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Oil Prices Climb as Iran Threatens Gulf Energy Infrastructure 
U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data 
Brent Oil Tops $100 as Middle East Conflict Threatens Supply 
Fitch Eyes Japan Budget for Fiscal Discipline 
Asian Currencies Steady as Yen Holds Firm, Oil Tops $100 
Hormuz Shipping Slows as Iran Threats Lift Oil Risks 
Gold Prices Rise as Yen Rally Weakens Dollar 
Gold Prices Steady Ahead of U.S. Inflation Data and Fed Decision 
Add as a preferred source on Google
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S. pharmaceutical giant. This investment comes as Pfizer contends with declining sales of its COVID-19 vaccines and treatments, underwhelming sales for its RSV vaccine, and failed clinical trials for an obesity medication.
Former Pfizer Executives to Aid Starboard’s Efforts
Starboard has approached Ian Read, Pfizer’s CEO until 2019, and Frank D’Amelio, who served as CFO until 2021. Both former executives are interested in helping Starboard steer the company toward renewed growth.
Stock Price Decline Post-COVID Success
Albert Bourla, who became CEO in 2019, was key in partnering with BioNTech to develop Pfizer's COVID-19 vaccine. However, as pandemic demand wanes, the company’s stock has plummeted from approximately $41 to $28.58 as of last Friday, reflecting concerns over weakened vaccine demand and disappointing new product launches.
Aggressive Acquisitions Draw Scrutiny
Since 2020, Pfizer has made over $70 billion in acquisitions, including major deals like Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics for $5 billion, and Trillium for $2 billion. The acquisitions have raised investor concerns, especially regarding GBT’s sickle cell drug, which faced market withdrawal due to severe side effects and discontinuation of related studies.
Starboard’s History of Corporate Overhauls
Known for pushing changes in major companies like News Corp, Salesforce, and Match Group, Starboard Value's influence could lead to significant shifts in Pfizer's strategic direction.
The Wall Street Journal first reported Starboard’s Pfizer stake. Neither Pfizer nor Starboard has officially commented on the investment or potential next steps.
